CLBIO: Corline Biomedical AB - Summary | Jitta

Corline Biomedical AB

SWE:CLBIO

Price
kr18.20
Loss Chance
57.9%
1.77JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
25 / 107
250 / 616
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (29)
Recent Business Performance (19)
Financial Strength (44)
Return to Shareholders (0)
Competitive Advantage (21)
Jitta Signs
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 6.57% in the last year
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
1.77
100.00%
2.16
102.25%
2.89
152.39%
Pharmaceuticals
6.20
170.39%
2.06
100.00%
2.86
100.00%
COMPANY DESCRIPTION
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company also provides medical devices, such as coated stents and coated ablation catheter. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.